Compare Delta Air Lines, Inc. (DAL) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Heron Therapeutics Inc — how do they compare? Delta Air Lines, Inc. trades at $80.63 (market cap $54.02B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Delta Air Lines, Inc. is far larger — about 794.3× Heron Therapeutics Inc's market cap, and Delta Air Lines, Inc. pays a 1.05% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Heron Therapeutics Inc for 35 Days on average.
| DAL | HRTX | |
|---|---|---|
Market Cap | $54.02B | $68.01M |
Volume | 9,632,845 | 1,891,941 |
Sector | Industrials | Health |
52-Week High | $93.66 | $1.49 |
52-Week Low | $55.65 | $0.27 |
Typical Hold Time | 97 Days | 35 Days |
Enterprise Value | $69.34B | $174.75M |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.97, down 0.82% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters and maintains solid profitability with 5.78% net margin and 20.12% ROE. Recent news highlights competitive pressures from United and American Airlines' customer poaching efforts and Elon Musk's criticism over Delta's Wi-Fi provider choice.
DAL presents a compelling value opportunity with a P/E of 13.62 below industry averages and strong analyst consensus (82% buy ratings) targeting $103.36. However, rising fuel costs, competitive threats to premium customers, and bearish technical indicators create near-term headwinds. The upcoming Q3 earnings report on October 9 will be crucial for validating the company's margin resilience.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
